Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) have been given a consensus recommendation of “Moderate Buy” by the seventeen analysts that are presently covering the company, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, fourteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have covered the stock in the last year is $23.3571.

Several brokerages have commented on CMPS. Maxim Group raised their price objective on Compass Pathways from $12.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, May 15th. UBS Group set a $18.00 target price on shares of Compass Pathways in a research report on Thursday, May 7th. Stifel Nicolaus increased their price target on shares of Compass Pathways from $14.00 to $21.00 and gave the stock a “buy” rating in a research note on Tuesday, July 7th. TD Cowen reissued a “buy” rating on shares of Compass Pathways in a research report on Monday, June 1st. Finally, Canaccord Genuity Group boosted their price objective on shares of Compass Pathways from $18.00 to $20.00 and gave the stock a “buy” rating in a research note on Friday, June 26th.

Hedge Funds Weigh In On Compass Pathways

Several large investors have recently made changes to their positions in CMPS. EverSource Wealth Advisors LLC boosted its position in shares of Compass Pathways by 67.7% in the 1st quarter. EverSource Wealth Advisors LLC now owns 4,754 shares of the company’s stock worth $26,000 after purchasing an additional 1,920 shares in the last quarter. Persistent Asset Partners Ltd bought a new position in Compass Pathways during the 4th quarter valued at approximately $38,000. Parallel Advisors LLC raised its stake in Compass Pathways by 8,450.6% during the first quarter. Parallel Advisors LLC now owns 7,268 shares of the company’s stock valued at $40,000 after buying an additional 7,183 shares during the last quarter. Advisory Services Network LLC purchased a new position in Compass Pathways during the third quarter valued at $41,000. Finally, North Star Investment Management Corp. boosted its holdings in Compass Pathways by 1,354.0% in the first quarter. North Star Investment Management Corp. now owns 7,517 shares of the company’s stock worth $42,000 after acquiring an additional 7,000 shares in the last quarter. 46.19% of the stock is currently owned by hedge funds and other institutional investors.

Compass Pathways Stock Performance

Shares of CMPS stock opened at $13.38 on Wednesday. The stock has a fifty day moving average of $12.57 and a 200 day moving average of $9.44. Compass Pathways has a 52 week low of $3.97 and a 52 week high of $15.40. The firm has a market capitalization of $1.81 billion, a price-to-earnings ratio of -2.90 and a beta of 2.50. The company has a quick ratio of 1.30, a current ratio of 1.30 and a debt-to-equity ratio of 0.60.

Compass Pathways (NASDAQ:CMPS) last announced its earnings results on Wednesday, August 5th. The company reported ($1.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($1.49). As a group, research analysts expect that Compass Pathways will post -1.26 earnings per share for the current year.

Key Headlines Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright retained its Buy rating and $65 target price for Compass Pathways. The target remains well above recent trading levels and reflects the analyst’s longer-term confidence in the company’s pipeline and commercial potential.
• Neutral Sentiment: The reported short-interest data shows zero shares short and a zero-day short-interest ratio, while also reporting an undefined percentage increase. Because the figures appear internally inconsistent, they provide no reliable signal about near-term buying pressure or bearish sentiment.
• Negative Sentiment: HC Wainwright lowered its EPS forecasts across multiple periods, including Q3 2026 to $(0.43), FY2026 to $(1.58), FY2027 to $(1.56), FY2028 to $(0.23), FY2029 to $1.66, and FY2030 to $4.06. The largest revisions push back the expected earnings outlook: FY2028 changed from $1.64 to a loss, FY2029 fell from $3.78 to $1.66, and FY2030 declined from $6.59 to $4.06.

Compass Pathways Company Profile

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.